OptimizeRx Corp. (NASDAQ:OPRX) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• OptimizeRx Corp. has received a consensus rating of "Moderate Buy" from analysts, with a target price averaging $11.81.
• Recent upgrades from analysts include JMP Securities raising their price target from $14.00 to $20.00 and Zacks Research upgrading from "hold" to "strong-buy."
• Institutions hold a significant 76.47% stake in OptimizeRx, with Nisa Investment Advisors LLC increasing their stake by 600% in the second quarter.

OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve research firms that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $11.8125.

A number of equities analysts have weighed in on OPRX shares. JMP Securities boosted their price objective on OptimizeRx from $14.00 to $20.00 and gave the stock a "market outperform" rating in a research note on Monday, August 11th. Zacks Research raised shares of OptimizeRx from a "hold" rating to a "strong-buy" rating in a research report on Friday, September 5th. B. Riley restated a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Citigroup reaffirmed an "outperform" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Finally, Wall Street Zen raised shares of OptimizeRx from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd.

OptimizeRx Price Performance

OPRX stock opened at $17.79 on Wednesday. OptimizeRx has a 1 year low of $3.78 and a 1 year high of $19.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57. The firm has a market capitalization of $330.27 million, a PE ratio of -32.94 and a beta of 1.20. The business has a 50 day simple moving average of $15.09 and a 200-day simple moving average of $11.61.

Institutional Investors Weigh In On OptimizeRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC lifted its stake in shares of OptimizeRx by 600.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company's stock valued at $29,000 after purchasing an additional 1,818 shares during the last quarter. Quantbot Technologies LP purchased a new stake in OptimizeRx in the 2nd quarter valued at about $44,000. GAMMA Investing LLC acquired a new position in OptimizeRx in the first quarter valued at about $33,000. BNP Paribas Financial Markets boosted its stake in OptimizeRx by 119.2% during the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company's stock worth $55,000 after buying an additional 2,215 shares during the period. Finally, Corton Capital Inc. acquired a new stake in shares of OptimizeRx during the second quarter valued at about $138,000. Hedge funds and other institutional investors own 76.47% of the company's stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.